Medical image guidance developer group ReMAP said today it won FDA approval for the 7D surgical machine-vision image guidance system, now cleared for spinal surgery.
The ReMAP 07 team is a collaborative effort between Canadian medical device firm 7D Surgical, Celestica, Ryerson University and the Sunnybrook Research Institute to advance optical technologies used for their image-guided surgery system.
“It is my pleasure to announce the FDA 510(K) and Health Canada MDL clearance of our Machine-vision Image Guidance System, the first of several advanced optical imaging technologies in our commercialization pipeline. We are proud to be part of the ReMAP O7 project team and have directly benefited from ReMAP’s mission of accelerating commercialization through collaborations between industry experts and scientists,” 7D Surgical CEO Beau Standish said in a prepared statement.
“As products are being launched exponentially faster than ever before, the role of ReMAP is to accelerate time-to-market from researchers’ innovative ideas and emerging technologies at later stage technology readiness levels through to product commercialization. A collaboration of industry experts and scientists strengthens the ability for a start-up organization to accelerate the commercialization of their innovation developed in Canada for the global market. ReMAP is pleased to support the ReMAP O7 Team in this initiative. We are committed to making a significant contribution to Canada to help build its competitive advantage, create new highly skilled jobs and providing opportunities to build export-ready products that will have long-term economic benefit,” ReMAP exec director Irene Sterian said in a press release.